A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings
- 28 February 2005
- journal article
- clinical trial
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 129 (2) , 423-428
- https://doi.org/10.1016/j.jtcvs.2004.06.048
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- The registry of the international society for heart and lung transplantation: twentieth official adult lung and heart–lung transplant report—2003Published by Elsevier ,2003
- Predominant role for C5b-9 in renal ischemia/reperfusion injuryJournal of Clinical Investigation, 2000
- Pulmonary transplantationCurrent Opinion In Anesthesiology, 2000
- Antiinflammatory Effects of Soluble Complement Receptor Type 1 Promote Rapid Recovery of Ischemia/Reperfusion Injury in Rat Small IntestineClinical Immunology, 1999
- Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swineThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Major Histocompatibility Complex Expression and Lung Ischemia-Reperfusion in RatsThe Annals of Thoracic Surgery, 1996
- Early Lung Allograft Function in Twin Recipients From the Same Donor: Risk Factor AnalysisThe Annals of Thoracic Surgery, 1996
- Requirement and role of C5a in acute lung inflammatory injury in rats.Journal of Clinical Investigation, 1996
- Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8.Journal of Clinical Investigation, 1995
- Complement in the Pathophysiology of Human DiseaseNew England Journal of Medicine, 1987